PMID- 24685639
OWN - NLM
STAT- MEDLINE
DCOM- 20150128
LR  - 20181202
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 734
DP  - 2014 Jul 5
TI  - N-terminal 5-mer peptide analog P165 of amyloid precursor protein inhibits 
      UVA-induced MMP-1 expression by suppressing the MAPK pathway in human dermal 
      fibroblasts.
PG  - 1-8
LID - S0014-2999(14)00234-9 [pii]
LID - 10.1016/j.ejphar.2014.03.028 [doi]
AB  - Exposure to ultraviolet (UV) radiation leads to a progressive increase in dermal 
      damage through the degradation of collagen, which is mediated by matrix 
      metalloproteinases (MMPs). UV radiation alters the intracellular signaling events 
      that regulate the elaboration of MMPs. Our previous study showed that P165, the 
      N-terminal 5-mer peptide analog of amyloid precursor protein, exerts a protective 
      effect on ultraviolet A (UVA)-induced loss of collagen type I in human dermal 
      fibroblasts (HDFs) by inhibiting the generation of intracellular reactive oxygen 
      species and MMP-1. In this study, we focused on specific signal transduction 
      pathways to elucidate the possible photoprotective mechanisms of P165 in 
      controlling MMP-1 inhibition. Results from western blot analyses indicated that 
      pretreatment with P165 dose-dependently inhibited UVA-induced phosphorylation of 
      extracellular regulated protein kinases (ERK), c-Jun N-terminal kniase (JNK), p38 
      mitogen-activated protein kinases (MAPKs), and the phosphorylation of their 
      downstream targets c-Jun and c-Fos. The photoprotective effects of P165 were 
      further demonstrated in collagen type I secretion and cellular senescence induced 
      by UVA irradiation. These findings suggest that P165 exerts photoprotective 
      activity in UVA-treated HDFs by regulating MMP-1 generation. This activity may be 
      mediated by inhibiting the MAPK signaling pathways. Thus, P165 is a potential 
      agent for the prevention of skin photoaging.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Dermatology and Venereology, Xuan Wu Hospital, Capital Medical 
      University, Beijing 100053, China.
FAU - Chen, Hui
AU  - Chen H
AD  - Department of Dermatology and Venereology, Xuan Wu Hospital, Capital Medical 
      University, Beijing 100053, China.
FAU - Wang, Wen
AU  - Wang W
AD  - Department of Pharmacology, Xuan Wu Hospital, Capital Medical University, Key 
      laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing 
      100053, China.
FAU - Wang, Rong
AU  - Wang R
AD  - Department of Central Laboratory, Xuan Wu Hospital, Capital Medical University, 
      Beijing 100053, China.
FAU - Liu, Zi-Lian
AU  - Liu ZL
AD  - Department of Dermatology and Venereology, Xuan Wu Hospital, Capital Medical 
      University, Beijing 100053, China.
FAU - Zhu, Wei
AU  - Zhu W
AD  - Department of Dermatology and Venereology, Xuan Wu Hospital, Capital Medical 
      University, Beijing 100053, China. Electronic address: zhuwei@xwh.ccmu.edu.cn.
FAU - Lian, Shi
AU  - Lian S
AD  - Department of Dermatology and Venereology, Capital Medical University, Beijing 
      100069, China. Electronic address: drlianshi@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140329
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Collagen Type I)
RN  - 0 (Oligopeptides)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases)
RN  - EC 3.2.1.23 (beta-Galactosidase)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
MH  - Amyloid beta-Protein Precursor/*chemistry
MH  - Collagen Type I/metabolism
MH  - Enzyme Activation/drug effects/radiation effects
MH  - Fibroblasts/cytology/drug effects/*metabolism/radiation effects
MH  - Gene Expression Regulation, Enzymologic/*drug effects
MH  - Humans
MH  - JNK Mitogen-Activated Protein Kinases/metabolism
MH  - MAP Kinase Signaling System/*drug effects/radiation effects
MH  - Matrix Metalloproteinase 1/*metabolism
MH  - Oligopeptides/*pharmacology
MH  - Phosphorylation/drug effects/radiation effects
MH  - Proto-Oncogene Proteins c-fos/metabolism
MH  - Skin/cytology
MH  - Ultraviolet Rays/*adverse effects
MH  - beta-Galactosidase/metabolism
OTO - NOTNLM
OT  - 5 peptide analog of amyloid precursor protein (P165)
OT  - 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside (PubChem CID: 44629973)
OT  - Acrylamide (PubChem CID: 6579)
OT  - Glutamine (PubChem CID: 5961)
OT  - Glutaraldehyde (PubChem CID: 3485)
OT  - Human dermal fibroblasts
OT  - MAPKs
OT  - Phenylmethylsulfonyl fluoride (PubChem CID: 4784)
OT  - Photoaging
OT  - Sodium fluoride (PubChem CID: 5235)
OT  - Sodium orthovanadate (PubChem CID: 61671)
OT  - Ultraviolet A
EDAT- 2014/04/02 06:00
MHDA- 2015/01/30 06:00
CRDT- 2014/04/02 06:00
PHST- 2014/02/12 00:00 [received]
PHST- 2014/03/07 00:00 [revised]
PHST- 2014/03/20 00:00 [accepted]
PHST- 2014/04/02 06:00 [entrez]
PHST- 2014/04/02 06:00 [pubmed]
PHST- 2015/01/30 06:00 [medline]
AID - S0014-2999(14)00234-9 [pii]
AID - 10.1016/j.ejphar.2014.03.028 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2014 Jul 5;734:1-8. doi: 10.1016/j.ejphar.2014.03.028. Epub 2014 
      Mar 29.